32 completed, 25 unknown, 18 recruiting, 7 terminated. 28 Phase 2, 22 Not applicable, 17 Phase 1, 5 Phase 3, 4 Phase 4.
Follow Bile Duct Cancer: new trials by email Literature Review of Bile Duct Cancer trials Research Report on Bile Duct Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2027-01-01 | 2026-08-05 |
| EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope Endoscopic ultrasound examination - Pancreatic Disease, Pancreatic Cancer | Not applicable | Recruiting | Orlando Health, Inc. | 140 | 2026-10-01 | 2026-10-20 |
| Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting - Bile Duct Cancer | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 36 | 2026-05-20 | 2026-05-26 |
| Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy - Pancreatic Cancer, Periampullary Cancer | Not applicable | Recruiting | Minia University | 194 | 2025-09-15 | 2026-10-01 |
| Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma | Phase 2 | Recruiting | Jinbo Yue | 38 | 2025-07-01 | 2026-10-15 |
| A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors KJ015 Injection (Subcutaneous Injection) - Gastric/Gastroesophageal Junction Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Shanghai Bao Pharmaceuticals Co., Ltd. | 66 | 2025-06-24 | 2025-06-25 |
| Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule - Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 100 | 2024-12-01 | 2024-12-12 |
| Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma Intraductal biliary radiofrequency ablation - Cholangiocarcinoma, Klatskin Tumor | Not applicable | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 130 | 2024-08-30 | 2026-09-09 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-05-08 | 2026-10-30 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors UCMYM802 Injection - Malignant Mesothelioma, Colorectal Cancer | Phase 1 | Unknown | UTC Therapeutics Inc. | 24 | 2024-03-05 | 2024-07-24 |
| Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE) Biliary Stricture, Bile Duct Cancer | Recruiting | Peking University Third Hospital | 99 | 2024-03-01 | 2025-05-28 | |
| Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 30 | 2024-02-13 | 2026-04-22 |
| Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials Bile Duct Cancer | Unknown | Power Life Sciences Inc. | 500 | 2024-02-01 | 2023-03-06 | |
| A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors CEA-targeted CAR-T cells - Colorectal Cancer, Esophagus Cancer | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 30 | 2023-08-11 | 2023-09-21 |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma Modified Blumgart Anastomosis in LPD, conventional Blumgart anastomosis in LPD - Ampullary Cancer, Bile Duct Cancer | Not applicable | Enrolling by invitation | Affiliated Hospital of Guangdong Medical University | 150 | 2023-07-01 | 2023-10-10 |
| Combined Treatment of Treated Bile Duct Cancer envolizumab , sovalteinib - Bile Duct Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 30 | 2023-07-01 | 2023-06-22 |
| A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) Solid Tumor, Advanced Solid Tumor | Recruiting | Centro di Riferimento Oncologico - Aviano | 782 | 2023-05-26 | 2023-09-13 | |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
Showing 20 of 93. Sign in to see all of them.
Bile Duct Neoplasms (93) · Pancreatic Neoplasms (49) · Cholangiocarcinoma (32) · Stomach Neoplasms (20) · Gallbladder Neoplasms (18) · Colorectal Neoplasms (17) · Liver Neoplasms (17) · Duodenal Neoplasms (12) · Esophageal Neoplasms (12) · Breast Neoplasms (11) · Ovarian Neoplasms (11) · Colonic Neoplasms (10) · Rectal Neoplasms (10) · Biliary Tract Neoplasms (9) · Carcinoma, Hepatocellular (9)
Biliary Tract Diseases (93) · Digestive System Diseases (93) · Neoplasms by Site (93) · Digestive System Neoplasms (92) · Bile Duct Diseases (90) · Neoplasms (88) · Biliary Tract Neoplasms (84) · Endocrine Gland Neoplasms (54) · Endocrine System Diseases (54) · Neoplasms by Histologic Type (49) · Neoplasms, Glandular and Epithelial (48) · Pancreatic Diseases (46) · Carcinoma (45) · Adenocarcinoma (41) · Gastrointestinal Diseases (39)
Gemcitabine (10) · Cisplatin (9) · durvalumab (6) · pembrolizumab (6) · Oxaliplatin (5) · Fluorouracil (4) · Capecitabine (3) · 1-phenyl-3,3-dimethyltriazene (2) · Leucovorin (2) · Liver Transplantation (2) · Long-Term Synaptic Depression (2) · Pancreaticoduodenectomy (2) · Radiosurgery (2) · Stents (2) · ceralasertib (2)
National Cancer Institute (NCI) (6) · Seoul National University Hospital (5) · Weill Medical College of Cornell University (4) · Chiba University (2) · Johannes Vermehren (2) · Wakayama Medical University (2) · Affiliated Hospital of Guangdong Medical University (1) · Ajou University School of Medicine (1) · Akita University Hospital (1) · Anne Noonan (1) · Beijing Biostar Pharmaceuticals Co., Ltd. (1) · Beth Israel Deaconess Medical Center (1) · Carisma Therapeutics Inc (1) · Case Comprehensive Cancer Center (1) · Cedars-Sinai Medical Center (1)
United States (38) · China (10) · South Korea (8) · Germany (6) · Australia (5) · Canada (5) · Japan (5) · France (4) · Sweden (3) · Denmark (2) · Italy (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1)
Michel Kahaleh, MD (5) · Tim F Greten, M.D. (4) · Jonathan M Hernandez, M.D. (2) · Katsunori Furukawa, MD (2) · Ali A Aghdassi, Professor (1) · Andrada Seicean, Professor (1) · Andrea Bullock, MD, MPH (1) · Anne M Noonan, MBBChBAO, MSc (1) · Anthony El-Khoueiry, M.D. (1) · Anthony J. Olszanski, M.D., RPh (1) · Antoine Adenis, MD, PhD (1) · Antonio Vigano, MD, MSc (1) · Ari D Baron, MD (1) · Arlette Da Silva, MD (1) · Bert Hildebrandt, MD (1)
PMID 17707751, PMID 20074698, PMID 21034892, PMID 21248633, PMID 24589090, PMID 25033929, PMID 25952086, PMID 26850262, PMID 26965712, PMID 27004243, PMID 27059973, PMID 27237786, PMID 27328985, PMID 27460387, PMID 28040257, PMID 28192597, PMID 29149611, PMID 29342492, PMID 29362244, PMID 30209610, PMID 30943124, PMID 31272934, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32740096, PMID 32878766, PMID 32919526, PMID 33104917, PMID 33142018, PMID 33836153, PMID 34662180, PMID 34990208, PMID 34995788, PMID 35114169, PMID 35274717, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36399037, PMID 36441083, PMID 36748723, PMID 38195752, PMID 38205877, PMID 38701690, PMID 38989414, PMID 39090600, PMID 39526177
2015 (2), 2023 (1), K07CA118576 (1), R01CA252211 (1)